Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
Nipocalimab – the first neonatal Fc receptor (FcRn) blocker to be studied…
Philips announces exchange ratio for 2025 dividend
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), today announced that the…
FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate
Exceptional track record across multiple clinical development programs for depression, three of…
Nanobiotix Joins the Euronext Tech Leaders Index
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext:…
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenstrm Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
June 01, 2026 08:05 ET | Source: Cellectar Biosciences, Inc. Approximately 80%…
LifeMD Appoints Umesh Sripad as Chief Technology Officer
Seasoned Technology Executive Brings More Than Two Decades of Large-Scale Digital Transformation…
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone…
Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight to Decode MET-Driven Biology and Resistance in Advanced NSCLC
Data include assessment of MET expression, tumor and immune pathway activity, and…
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
IMA401 achieved deep and durable responses in various indications, including melanoma and…
